MRD Monitoring in Lung Cancer After Resection

Recruiting now

Conditions studied: Lung Cancer

In brief

The conception of molecular residual disease (MRD) extending from hematologic tumor to solid tumors. Evidences supporting MRD evaluation for lung cancer by liquid biopsy has gradually accumulated, especially circulating tumor DNA (ctDNA). In this observational study, the investigators prospectively enroll stage I-IIIA non-small cell lung cancer (NSCLC) patients who underwent complete resection. Preoperative blood sample, tumor tissue and dynamic postoperative blood samples are collected continuously for MRD detection. This study aim to explore the prognostic value of MRD for stage I-IIIA NSCLC patients after complete resection.

Key facts

Study ID

NCT04976296

Run by

Guangdong Provincial People's Hospital

People needed

300

Starts

2021-09-01

Expected to finish

2027-12-30

Last updated by the study team

2022-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of histologically confirmed NSCLC (WHO 2015 classification) with resectable (stage I-IIIA) disease.
• Complete resection
• Age ≥18 years at the time of screening
• Capable of giving signed informed consent

You may not qualify if…

• Mixed small cell and NSCLC histology
• Rx, R1 or R2 resection
• History of other malignant tumors within 5 years

Where it is running

• Guangdong Lung Cancer Institute & Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.